The background of the slide features a silhouette of a mountain range against a vibrant sunset sky. The sky transitions from a deep blue at the top to a mix of orange, red, and purple near the horizon. Several hikers are visible as dark silhouettes against the bright sky, some standing on a ridge and others climbing a steep slope.

Oncocyte Investor Presentation

NASDAQ: OCX

Josh Riggs

CEO

Q4 2023

 **ONCOCYTE**[™]
Where Tomorrow **LIVES**

Forward Looking Statement

Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include, among others, those pertaining to the Company's development and commercial model (including expected margin and cost, reimbursement, strategic partnerships, global scalability, capital efficiency, accelerated adoption and clinical development), anticipated timing of product development and launch and upcoming milestones, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, the potential impact of COVID-19 on Oncocyte or its subsidiaries' financial and operational results, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte's third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients' use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte's Securities and Exchange Commission (SEC) filings, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Oncocyte Investor Summary

3 novel precision diagnostic tests for oncology and transplant, representing a **\$10B+** clinical market opportunity¹

- Differentiated, capital-light commercial model focused on profitability, not just revenue
- Competitive proprietary, patented technologies and published clinical data
- Potential disruption of mature diagnostic markets with strong existing reimbursement, limiting commercial risk
- **CMS Coverage VitaGraft Kidney**
- **First RUO product launch targeted for 1H 2024**
- Multiple additional value creating milestones expected over next four quarters



Differentiated Strategy Focused on Profitability

Oncocyte Diagnostic Product Market Opportunity

Three novel diagnostic tests addressing large reimbursed markets

Transplant

VitaGraft™

Is the transplanted organ damaged?

\$500M est. revenue currently generated by competitors

\$2B* est. US market

\$4B* est. worldwide

Well established path to reimbursement under blanket LCD

Oncology

DETERMA IO™

Will patient benefit from immunotherapy?

\$1.5B est. revenue generated currently by competing tests

\$2B est.** incremental US market

\$4B est.** incremental worldwide market

Submitted for reimbursement in 4Q22

DETERMA CNI™

Is the immunotherapy drug working?

\$200M est. revenue generated currently by competing tests

\$4B est.** US market

\$8B est.** worldwide

Well established path to reimbursement under blanket LCD

Differentiated, Capital-light Commercial Model

Development and commercial model optimized for speed to market, product margin, and capital efficiency

Development

Service Lab

- Clinical development
- **Supports FDA pathway**
- Publications
- Early access programs
- Reimbursement
- Patent applications

Commercial

Kitted Product

- Strategic partner distributes product
- **Product targeted 70%+ gross margin**
- Globally scalable through partner
- Costs limited to product development
- Tests run on market-leading diagnostic platforms


Diagnostic Development and Commercialization

Kitted products are packaged and distributable globally

Traditional Model

Selling a central lab service to physicians

Large
Sales
Force



- No scale economies
- Geographically locked

12,000+ US
call points,
Low-volume¹




Capital
intensive,
loss-making



Oncocyte Approach

Selling a high-margin kitted product to existing labs

Small
Sales
Force



- Kitted product
- Partnering commercial model
- Globally scalable

<1,000 US
call points,
Higher-volume¹

Capital light,
Focus on margin
and profitability



Transplant Central Lab Service Example


Transplant centers have volume and capability just missing the technology

Highly Concentrated Market

<100 transplant centers in US market generate approx. 80% of the volume¹

High Capability Labs

Most transplant centers are in academic settings with sophisticated central labs



Sending over 100,000 tests/yr.² to two labs in California **because they don't have a way to run testing in house**



Oncocyte Going Forward

\$20 – 30M

Anticipated breakeven
at modest revenue

- Our service lab infrastructure remains lean, supporting reimbursement and clinical development
- Partners share costs of commercializing our distributable kitted product
- High-margin, low-complexity business model based on product revenue
- Significantly greater scalability should lead to substantially higher operating margins



Product Spotlight

VitaGraft™


For cause testing example

PROBLEM:

Current Standard of Care performs biopsies on patients that may not need one leading to increased overall healthcare costs and increased risk of complications

Problems with biopsy

- Expensive compared to blood test
- Increases risk of complications including hospitalization
- Invasive procedure



SOLUTION:

All patients newly transplanted and being monitored for rejection are eligible for VitaGraft testing

Estimated to be \$2B¹ US market, with current competitors making up ~\$500M² of the market



Transplant - High Demand, Fast Growing Space

- Central service lab competitors currently generating \$500M in annual revenue from kidney & heart transplant tests¹
- **Highly litigious market limits new market entrants**
- Labs without an IP position are limited, generating demand to license and distribute VitaGraft
- VitaGraft adoption may be accelerated by the following factors:
 - Ease-of-use and turn-around-time advantages over current tests
 - Service lab distribution partners may already have larger sales forces than transplant incumbents
 - VitaGraft runs on market leading platforms

VitaGraft

**Planned VitaGraft
launching in 2H 2023,
expected to drive revenue
growth starting in 2024.**

ONCOCYTE'S VITAGRAFT KIDNEY TRANSPLANT DIAGNOSTIC TEST RECEIVES CMS COVERAGE

IRVINE, CA / ACCESSWIRE / August 28, 2023 / [Oncocyte Corporation](#) (NASDAQ:OCX), a precision diagnostics company, today announced that Palmetto GBA, the Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services (CMS), has issued a positive coverage decision for the Company's VitaGraft Kidney™ diagnostic test, confirming that the test has met the criteria for coverage under MolDX: Molecular Testing for Solid Organ Allograft Rejection (L38568).

First coverage decision for our proprietary technology opens largest transplant market and is driving partnering conversations

ONCOCYTE'S VITAGRAFT KIDNEY IDENTIFIES TRANSPLANT REJECTION 10 MONTHS EARLIER

IRVINE, CA / ACCESSWIRE / September 18, 2023 / [Oncocyte Corporation](#) (NASDAQ:OCX), a precision diagnostics company, today announced the presentation of significant new clinical data at the European Society of Organ Transplant (ESOT) conference.

The data was generated from a randomized interventional clinical trial conducted by Charité, a leading transplant and research institution in Germany. Interim results showed that monitoring kidney transplant patients with Oncocyte's VitaGraft Kidney donor-derived cell-free DNA (dd-cfDNA) assay identified antibody-mediated rejection (ABMR) 10 months sooner than standard of care monitoring protocols.

First test to report out data from an interventional study raising the bar for clinical validation and expands potential applications

DETERMA IO™ + DETERMA CNI™

Late-stage cancer therapy is a \$100B decision that is only getting more complicated



- Combines three elements of the tumor micro-environment into one easy to interpret score
- Competitors currently generating over \$1B in annual revenue from therapy selection
- **Over 13k publications on tumor micro-environment in 2022**
- Built on well distributed PCR platform
- **Landmark SWOG study in process**
- **Targeted 2024 Launch**



- Blood test, uses common tumor biology, copy number variation, to identify response to therapy
- **Multiple competitors acquired for over \$400M each within last 3 years¹**
- \$100's of millions in clinical revenue today²
- Reimbursement for multiple tests in multiple indications
- CNI is built on most widely available NGS platform in the world
- **Targeted 2024 Launch**



Next Steps

Recent Accomplishments Slide

➔ Approx **50% reduction** in operating expense

➔ **Financial Highlights**

- \$19.1M on hand at end of Q2
- Runway well into 2024
- Projected quarterly burn below \$5M

➔ Coverage for VitaGraft Kidney - **\$2B US Market**

➔ Manufacturing of Transplant RUO product started in Q2

➔ **Clinical Development**


- Landmark SWOG study in Triple-Negative Breast Cancer ongoing
- Randomized interventional data presented at ESOT

Four Quarter Look-Forward

Rapid progress on milestones and market access

VitaGraft

- Manufacturing
- Pre-market activities
- Commercialization



DETERMA IO™

- SWOG study
- Kit development

DETERMA CNI™

- NSCLC Study
- Kit development

Q4 2023 Major Milestone Opportunities

Achieve coverage for:



Planned Milestones -

- Complete manufacturing conversion of VitaGraft into a kitted product
- Announce a strategic or distribution partner for VitaGraft
- Begin processing DetermaIO pivotal 862 patient study in triple negative breast cancer
- Publication of pancreatic data for DetermaCNI

Experienced Leadership Team

Pioneering Molecular Diagnostics



JOSH RIGGS
President & Chief
Executive Officer



EKKEHARD SCHÜTZ,
MD, PHD, FAAC
Chief Science Officer



YUH-MIN (JOHNSON)
CHIANG, PHD
Chief Technology Officer

ThermoFisher
SCIENTIFIC

life
technologies™

 **Cepheid.**
A better way.


FOUNDATION
MEDICINE

 **GEORG-AUGUST-UNIVERSITÄT**
GÖTTINGEN IN PUBLICA COMMODO
SEIT 1737

 **ALVEO**
TECHNOLOGIES, Inc.

 **Bethesda**
group

Oncocyte Investor Summary

3 novel precision diagnostic tests for oncology and transplant, representing a **\$10B+** clinical market opportunity¹

- Differentiated, capital-light commercial model focused on profitability, not just revenue
- Competitive proprietary, patented technologies and published clinical data
- Potential disruption of mature diagnostic markets with strong existing reimbursement, limiting commercial risk
- **CMS Coverage VitaGraft Kidney**
- **First RUO product launch targeted for 1H 2024**
- Multiple additional value creating milestones expected over next four quarters

**JOSHUA RIGGS,
PRESIDENT & CEO**

JRIGGS@ONCOCYTE.COM

Thank You



 **ONCOCYTE™**

